BioRestorative Therapies, Inc.
BRTX
$2.74
-$0.06-2.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 18.37% | 66.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.37% | 66.10% | |||
| Cost of Revenue | 362.50% | -84.91% | |||
| Gross Profit | -12.22% | 1,400.00% | |||
| SG&A Expenses | 21.31% | 9.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.34% | 3.34% | |||
| Operating Income | 11.49% | -3.14% | |||
| Income Before Tax | 32.83% | -5.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.83% | -5.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.83% | -5.57% | |||
| EBIT | 11.49% | -3.14% | |||
| EBITDA | 11.64% | -3.18% | |||
| EPS Basic | 63.08% | 1.25% | |||
| Normalized Basic EPS | 63.07% | 1.25% | |||
| EPS Diluted | 63.08% | 1.25% | |||
| Normalized Diluted EPS | 63.07% | 1.25% | |||
| Average Basic Shares Outstanding | 81.90% | 6.91% | |||
| Average Diluted Shares Outstanding | 81.90% | 6.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||